
**Expert Committee on Drug Dependence
Thirty-sixth Meeting
Geneva, 16-20 June 2014**



1. Comments based on the review report

a. Evidence on dependence and abuse potential

No studies have examined the dependence and abuse potential of 25B-NBOMe in vitro, in animals or in humans.

b. Risks to individual and society because of misuse

Subjective effects were similar to comparison serotonergic hallucinogens, though higher 'negative effects while high' and greater 'value for money' were reported.

c. Magnitude of the problem in countries (misuse, illicit production, smuggling etc)

25B-NBOMe use and/or seized material has been reported in 10 countries.

d. Need of the substance for medical (including veterinary) practice

25B-NBOMe has no recorded therapeutic applications or medical use.

e. Need of the substance for other purposes (e.g. industrial)

25B-NBOMe has no industrial use.

f. Measures taken by countries to curb misuse

25B-NBOMe is currently controlled under drug control legislation in 10 countries.

g. Impact if this substance is scheduled

If 25B-NBOMe was placed under international control, at least some countries would have the laboratory capacity to identify the substance.

2. Additional information to the critical review report

Two male patients (17 and 31 years of age) had ingested drugs labeled as 'NBOMe' or 'Holland film' and developed confusion, agitation, hypertension, tachycardia, hyperthermia, sweating and dilated pupils. Other features included convulsion,

rhabdomyolysis and deranged liver function ([Clin Toxicol \(Phila\)](#). 2014 Apr 29. [Epub ahead of print]).

3. **Other comments or opinions**

None.

4. **Expert reviewer's view on scheduling with rationale**

No studies have examined the dependence and abuse potentials of 25B-NBOMe in vitro, in animals or in humans. A death associated with 25B-NBOMe has been reported. However, the information available is not sufficient to recommend international control of 25B-NBOMe.